CASE WESTERN RESERVE UNIVERSITY CORPORATION

Their core work

Case Western Reserve University (CWRU) is a major US research university based in Cleveland, Ohio, with strong biomedical and life sciences research programs. In their H2020 participation, they contributed expertise in biological mechanisms of human disease — spanning brain disease, cancer, and metabolic disorders — as well as advanced microbiome and immunology research. Their involvement in the MISTRAL project positions them as a scientific contributor to systems-level analysis of HIV-1 risk and chronic disease, integrating gut microbiome data with biomarkers and bioinformatics. They operate as a specialist research partner, bringing deep domain knowledge rather than coordination or management capacity.

What they specialise in

How they've shifted over time

In their early H2020 engagement (2015-2020), CWRU participated in a structured doctoral training programme centred on the biological bases of human disease — brain disorders, cancer, and metabolic conditions — with an emphasis on researcher education and international mobility. Their more recent project (2020-2025) marks a clear shift toward translational, data-driven immunology: gut microbiome profiling, HIV-1 risk stratification, biomarker discovery, and bioinformatics. The trajectory moves from broad disease biology education toward specialised, systems-level research on immune dysfunction and chronic disease.

CWRU is moving toward precision immunology and microbiome-driven disease stratification, making them a relevant partner for consortia working on infectious disease, chronic inflammation, or biomarker-based diagnostics.

How they like to work

CWRU has not led any H2020 projects, participating either as a standard partner or third party — a pattern consistent with a US institution joining European consortia as a specialist contributor rather than a coordinator. Their consortium exposure is relatively broad (35 unique partners across 15 countries) despite only two projects, suggesting they join large international research networks. This makes them a straightforward partner to work with: they bring expertise and capacity without seeking administrative control.

Despite only two projects, CWRU has connected with 35 unique consortium partners across 15 countries — an unusually wide network for such limited EU participation, reflecting the large multi-partner structure of both projects. Their reach is genuinely global, bridging US research capacity into European-led consortia.

What sets them apart

CWRU is one of the relatively few US universities with direct H2020 project participation, giving European consortia a credible transatlantic research partner without needing to build a new relationship from scratch. Their combination of classical biomedical disease research and more recent microbiome-immunology expertise is relatively uncommon in a single institution. For consortia targeting HIV, chronic inflammation, or gut-brain axis research, CWRU offers both experimental and computational capacity.

Highlights from their portfolio

• MISTRAL
  The largest funded project (EUR 806,560 EC contribution) and the most scientifically specific — combining microbiome profiling, HIV-1 risk, inflammaging, and bioinformatics in a single RIA, representing CWRU's most substantial and recent EU research engagement.
• Bio4Med
  An MSCA-COFUND doctoral programme covering brain disease, cancer, and metabolic disorders — notable for its researcher training focus and international mobility component, showing CWRU's early role as a transatlantic training partner.